DEMECAN Introduces First Live Rosin Products Into German Medical Cannabis Market
DEMECAN is one of the top companies in the German cannabis industry and specializes in the production and distribution of medical cannabis. The company holds a license for the cultivation and processing of cannabis for medical purposes in Germany and operates a production facility that supplies high-quality cannabis products to pharmacies and patients in Germany and Europe.
The company recently announced that it has introduced a line of fresh extract live rosin products into the legal German medical cannabis market, which is a major milestone not only for DEMECAN, but also for the wider German medical industry.
“The Saxon company DEMECAN – the only independent producer of medical cannabis in Germany – is introducing DEMECAN FE 800 No.1, the first fresh extract produced using the Live Rosin process, into regulated medical care in Germany.” the company stated in a press release (translated from German to English). “While this manufacturing process has already established itself as a high-quality alternative in North America, it is a market premiere in Europe.”
“They are obtained exclusively from fresh plant material, avoiding heat, light, and drying to preserve the plant’s complete active ingredient profile. The result is a creamy extract with over 90% active ingredients, consisting of cannabinoids and terpenes. Production is purely mechanical and solvent-free, meaning no butane, ethanol, or CO2 is used. This production method distinguishes the fresh extract from other extracts and makes it the ideal basis for patient-specific formulations, for example, for chronic pain patients or in palliative care.” the company also stated.
Live rosin products are widely available in the United States and Canada, both for medical and recreational use. Other forms of solventless extracts include bubble hash and kief, although live rosin is the most popular among patients and consumers in North America, according to available market data.
“With DEMECAN FE 800 No.1, we are bringing an innovative and internationally proven product into regulated medical care in Germany – safe, effective, and of pharmaceutical quality. As the first and only manufacturer to produce a fresh extract using the Live Rosin process under GMP conditions in Germany, we are setting new standards for therapeutic cannabis extracts. In doing so, we are not only strengthening supply security, but also Germany’s position as a center of innovation in the field of medical cannabis research and application,” explains Dr. Adrian Fischer, CEO of DEMECAN.
“This first market launch demonstrates that we are leading the medical cannabis market in Germany with innovative products,” Fischer continued.
DEMECAN FE 800 No. 1 has a tetrahydrocannabinol (THC) content of 80%, and a cannabidiol (CBD) content of roughly 5%. The terpene content of DEMECAN’s live rosin is approximately 6%.
